• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Investigation of CFTR Function in Human Nasal Epithelial Cells Informs Personalized Medicine.对人类鼻上皮细胞中CFTR功能的研究为个性化医疗提供依据。
Am J Respir Cell Mol Biol. 2024 Nov;71(5):577-588. doi: 10.1165/rcmb.2023-0398OC.
2
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.12岁及以上囊性纤维化患者使用万扎卡托-替扎卡托-地替瓦卡托与依列卡托-替扎卡托-艾伐卡托的对比研究(SKYLINE试验VX20 - 121 - 102和VX20 - 121 - 103):两项随机、活性对照3期试验的结果
Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.
3
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.囊性纤维化的增效剂(针对III类和IV类突变的特定疗法)。
Cochrane Database Syst Rev. 2015 Mar 26(3):CD009841. doi: 10.1002/14651858.CD009841.pub2.
4
Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis.囊性纤维化患者中 CFTR 调节剂诱导的汗液氯化物浓度的异质性。
J Cyst Fibros. 2024 Jul;23(4):676-684. doi: 10.1016/j.jcf.2024.02.001. Epub 2024 Feb 15.
5
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(有或没有增效剂)。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
6
Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR.依列卡福妥/替扎卡福妥/依伐卡托支持对携带ΔI1023-V1024-CFTR的囊性纤维化患者进行治疗。
Int J Mol Sci. 2025 May 31;26(11):5306. doi: 10.3390/ijms26115306.
7
Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis.依列卡福妥、替扎卡福妥和依伐卡福妥在成人囊性纤维化真实世界队列中的群体药代动力学
Clin Pharmacokinet. 2025 May 22. doi: 10.1007/s40262-025-01516-1.
8
The potentiator ivacaftor is essential for pharmacological restoration of F508del-CFTR function and mucociliary clearance in cystic fibrosis.增效剂依伐卡托对于恢复囊性纤维化中F508del-CFTR功能和黏液纤毛清除功能的药理学作用至关重要。
JCI Insight. 2025 Apr 22;10(10). doi: 10.1172/jci.insight.187951. eCollection 2025 May 22.
9
Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis.肺部之外。依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化儿童鼻窦疾病的影响。
Int Forum Allergy Rhinol. 2025 Jul;15(7):715-723. doi: 10.1002/alr.23557. Epub 2025 Mar 6.
10
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase-1 in Children With Cystic Fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化儿童粪便弹性蛋白酶-1的影响。
Pediatr Pulmonol. 2025 Jun;60(6):e71156. doi: 10.1002/ppul.71156.

引用本文的文献

1
Diseases Common in Persons With Cystic Fibrosis Among CFTR Heterozygotes.CFTR杂合子中囊性纤维化患者常见的疾病。
JAMA Intern Med. 2025 Jun 16. doi: 10.1001/jamainternmed.2025.1853.

本文引用的文献

1
In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.在囊性纤维化患者中发现的 655 种 CFTR 变体的体外调节剂反应性。
J Cyst Fibros. 2024 Jul;23(4):664-675. doi: 10.1016/j.jcf.2024.02.006. Epub 2024 Feb 22.
2
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.对囊性纤维化患者进行基因分型,以指导依列卡福/替扎卡福/艾伐卡福的超说明书处方。
Eur Respir J. 2023 Oct 19;62(4). doi: 10.1183/13993003.00110-2023. Print 2023 Oct.
3
Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X.使用腺嘌呤碱基编辑和同源非依赖性靶向整合策略来纠正囊性纤维化致病变体 W1282X。
Hum Mol Genet. 2023 Nov 17;32(23):3237-3248. doi: 10.1093/hmg/ddad143.
4
Protospacer modification improves base editing of a canonical splice site variant and recovery of CFTR function in human airway epithelial cells.原间隔序列修饰可改善典型剪接位点变体的碱基编辑,并恢复人气道上皮细胞中CFTR的功能。
Mol Ther Nucleic Acids. 2023 Jun 29;33:335-350. doi: 10.1016/j.omtn.2023.06.020. eCollection 2023 Sep 12.
5
Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses.原代鼻腔上皮细胞感染可区分致死性和季节性人冠状病毒。
Proc Natl Acad Sci U S A. 2023 Apr 11;120(15):e2218083120. doi: 10.1073/pnas.2218083120. Epub 2023 Apr 6.
6
Redox Homeostasis in Well-differentiated Primary Human Nasal Epithelial Cells.人源高分化原代鼻上皮细胞中的氧化还原稳态
J Cell Signal. 2022;3(4):193-206. doi: 10.33696/signaling.3.083.
7
Resveratrol and Astaxanthin Protect Primary Human Nasal Epithelial Cells Cultured at an Air-liquid Interface from an Acute Oxidant Exposure.白藜芦醇和虾青素可保护在气液界面培养的原代人鼻上皮细胞免受急性氧化剂暴露的影响。
J Cell Signal. 2022;3(4):207-217. doi: 10.33696/signaling.3.084.
8
Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry.地氯雷他定是一种获得美国食品药品监督管理局批准的阳离子两亲性药物,通过阻断病毒进入,可在细胞培养物和原代人鼻腔上皮细胞中抑制 SARS-CoV-2 感染。
Sci Rep. 2022 Dec 6;12(1):21053. doi: 10.1038/s41598-022-25399-5.
9
In vivo correction of cystic fibrosis mediated by PNA nanoparticles.肽核酸纳米颗粒介导的囊性纤维化体内校正。
Sci Adv. 2022 Oct 7;8(40):eabo0522. doi: 10.1126/sciadv.abo0522. Epub 2022 Oct 5.
10
Cilia Stimulatory and Antibacterial Activities of T2R Bitter Taste Receptor Agonist Diphenhydramine: Insights into Repurposing Bitter Drugs for Nasal Infections.T2R苦味受体激动剂苯海拉明的纤毛刺激和抗菌活性:将苦味药物重新用于治疗鼻腔感染的见解
Pharmaceuticals (Basel). 2022 Apr 6;15(4):452. doi: 10.3390/ph15040452.

对人类鼻上皮细胞中CFTR功能的研究为个性化医疗提供依据。

Investigation of CFTR Function in Human Nasal Epithelial Cells Informs Personalized Medicine.

作者信息

Pion Audrey, Kavanagh Erin, Joynt Anya T, Raraigh Karen S, Vanscoy Lori, Langfelder-Schwind Elinor, McNamara John, Moore Brooke, Patel Shivani, Merlo Kate, Temme Renee, Capurro Valeria, Pesce Emanuela, Merlo Christian, Pedemonte Nicoletta, Cutting Garry R, Sharma Neeraj

机构信息

Department of Genetic Medicine.

Department of Pediatrics, and.

出版信息

Am J Respir Cell Mol Biol. 2024 Nov;71(5):577-588. doi: 10.1165/rcmb.2023-0398OC.

DOI:10.1165/rcmb.2023-0398OC
PMID:39012815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11568479/
Abstract

We broaden the clinical versatility of human nasal epithelial (HNE) cells. HNEs were isolated from 10 participants harboring () variants: 9 with rare variants (Q359R [=2], G480S, R334W [=5], and R560T) and 1 harboring R117H;7T;TG10/5T;TG12. Cultures were differentiated at the air-liquid interface. CFTR function was measured in Ussing chambers at three conditions: baseline, ivacaftor, and elexacaftor + tezacaftor + ivacaftor (ETI). Four participants initiated modulators. Q359R HNEs had 5.4% (% wild-type) baseline CFTR function and 25.5% with ivacaftor. With therapy, sweat [Cl] decreased and symptoms resolved. G480S HNEs had 4.1% baseline and 32.1% CFTR function with ETI. Clinically, forced expiratory volume in 1 second increased and sweat [Cl] decreased (119 to 46 mmol/L) with ETI. cultures derived from 5 participants harboring R334W showed a moderate increase in CFTR function with exposure to modulators. For one of these participants, ETI was begun ; symptoms and forced expiratory volume in 1 second improved. The c.1679G>C (R560T) HNEs had less than 4% baseline CFTR function and no modulator response. RNA analysis confirmed that c.1679G>C completely missplices. A symptomatic patient harboring R117H;7T;TG10/5T;TG12 exhibited reduced CFTR function (17.5%) in HNEs, facilitating a diagnosis of mild CF. HNEs responded to modulators (ivacaftor: 32.8%, ETI: 55.5%), and, since beginning therapy, lung function improved. We reaffirm HNE use for guiding therapeutic approaches, inform predictions on modulator response (e.g., R334W), and closely assess variants that affect splicing (e.g., c.1679G>C). Notably, functional studies in HNEs harboring R117H;7T;TG10/5T;TG12 facilitated a diagnosis of mild CF, suggesting the use for HNE functional studies as a clinical diagnostic test.

摘要

我们拓宽了人鼻上皮(HNE)细胞的临床应用范围。从10名携带()变体的参与者中分离出HNE细胞:9名携带罕见变体(Q359R[=2]、G480S、R334W[=5]和R560T),1名携带R117H;7T;TG10/5T;TG12。细胞培养在气液界面进行分化。在三种条件下于尤斯灌流小室中测量CFTR功能:基线、依伐卡托,以及依列卡托+替扎卡托+依伐卡托(ETI)。4名参与者开始使用调节剂。Q359R HNE细胞的基线CFTR功能为5.4%(野生型百分比),使用依伐卡托时为25.5%。经过治疗,汗液[Cl]降低,症状缓解。G480S HNE细胞的基线CFTR功能为4.1%,使用ETI时为32.1%。临床上,使用ETI后,一秒用力呼气量增加,汗液[Cl]降低(从119降至46 mmol/L)。来自5名携带R334W变体参与者的细胞培养物在接触调节剂后CFTR功能有适度增加。其中一名参与者开始使用ETI;症状和一秒用力呼气量均有改善。c.1679G>C(R560T)HNE细胞的基线CFTR功能低于4%,且对调节剂无反应。RNA分析证实c.1679G>C完全剪接错误。一名携带R117H;7T;TG10/5T;TG12的有症状患者的HNE细胞中CFTR功能降低(17.5%),有助于诊断轻度囊性纤维化(CF)。HNE细胞对调节剂有反应(依伐卡托:32.8%,ETI:55.5%),并且自开始治疗以来,肺功能有所改善。我们重申使用HNE细胞来指导治疗方法、预测调节剂反应(例如R334W),并密切评估影响剪接的变体(例如c.1679G>C)。值得注意的是,对携带R117H;7T;TG10/5T;TG12的HNE细胞进行的功能研究有助于诊断轻度CF,表明将HNE细胞功能研究用作临床诊断测试。